JP2019516675A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516675A5
JP2019516675A5 JP2018555634A JP2018555634A JP2019516675A5 JP 2019516675 A5 JP2019516675 A5 JP 2019516675A5 JP 2018555634 A JP2018555634 A JP 2018555634A JP 2018555634 A JP2018555634 A JP 2018555634A JP 2019516675 A5 JP2019516675 A5 JP 2019516675A5
Authority
JP
Japan
Prior art keywords
peg
pharmaceutically acceptable
acceptable salt
ala
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018555634A
Other languages
English (en)
Japanese (ja)
Other versions
JP7134093B2 (ja
JP2019516675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2017/050475 external-priority patent/WO2017181277A1/en
Publication of JP2019516675A publication Critical patent/JP2019516675A/ja
Publication of JP2019516675A5 publication Critical patent/JP2019516675A5/ja
Application granted granted Critical
Publication of JP7134093B2 publication Critical patent/JP7134093B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018555634A 2016-04-19 2017-04-18 ペグ化バイオアクティブペプチド及びその使用 Expired - Fee Related JP7134093B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324600P 2016-04-19 2016-04-19
US62/324,600 2016-04-19
PCT/CA2017/050475 WO2017181277A1 (en) 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2019516675A JP2019516675A (ja) 2019-06-20
JP2019516675A5 true JP2019516675A5 (enExample) 2021-11-11
JP7134093B2 JP7134093B2 (ja) 2022-09-09

Family

ID=60039750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018555634A Expired - Fee Related JP7134093B2 (ja) 2016-04-19 2017-04-18 ペグ化バイオアクティブペプチド及びその使用

Country Status (18)

Country Link
US (2) US10918730B2 (enExample)
EP (1) EP3445778B1 (enExample)
JP (1) JP7134093B2 (enExample)
KR (1) KR102520348B1 (enExample)
CN (1) CN109153712B (enExample)
AU (1) AU2017254754B2 (enExample)
BR (1) BR112018070929A2 (enExample)
CA (1) CA3021231A1 (enExample)
DK (1) DK3445778T3 (enExample)
ES (1) ES2824781T3 (enExample)
HU (1) HUE052802T2 (enExample)
IL (1) IL262356B2 (enExample)
MX (1) MX2018012716A (enExample)
PL (1) PL3445778T3 (enExample)
PT (1) PT3445778T (enExample)
RU (1) RU2748576C2 (enExample)
SG (1) SG11201808880PA (enExample)
WO (1) WO2017181277A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205498A1 (en) 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease
CN116194344B (zh) 2020-10-09 2026-06-30 奥托立夫开发公司 安全气囊装置
CN114195881B (zh) * 2021-12-16 2022-09-16 浙江湃肽生物股份有限公司 一种制备醋酸舍莫瑞林的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4914189A (en) 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
DE3726324A1 (de) 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
NZ238748A (en) 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
US5847006A (en) 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
DK0828758T3 (da) 1995-05-26 2002-01-07 Theratechnologies Inc Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
KR20020047096A (ko) 1999-07-26 2002-06-21 크로커 사무엘 에스 초활성 돼지 성장 호르몬 분비 호르몬 유사체
US7256258B2 (en) 2000-10-05 2007-08-14 Ares Trading S.A. Regioselective liquid phase pegylation
EP1539959A2 (en) 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh analogues
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US8293708B2 (en) * 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
BRPI0915142A8 (pt) 2008-06-12 2018-01-02 Syntaxin Ltd Polipeptídeos, ácido nucleico e usos dos mesmos
US20110288011A1 (en) 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
CN104946659A (zh) * 2015-03-27 2015-09-30 杭州北斗生物技术有限公司 重组人生长激素的制备方法及其peg化修饰物的制备方法
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Similar Documents

Publication Publication Date Title
JP2014521684A5 (enExample)
RU2471867C2 (ru) Гиалуронидаза и способ ее применения
JP2013515055A5 (enExample)
JP2013515057A5 (enExample)
EP2326341B1 (en) Oxytocin formulations and uses thereof
JP2014530868A5 (enExample)
JP2015502336A5 (enExample)
HRP20140616T1 (hr) Peptidni analog oksintomodulina
JP2016512213A5 (enExample)
JP2011526886A5 (enExample)
JP2020518287A5 (enExample)
JP2013518090A5 (enExample)
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
JP2013517307A5 (enExample)
US20150299286A1 (en) Glutamic acid-stabilized insulin analogues
JP2012500001A5 (enExample)
CN106232616A (zh) 两亲性合成抗菌肽、其药物组合物及其用途
JP2019533722A5 (enExample)
WO2014081702A4 (en) Synthetic linear apelin mimetics for the treatment of heart failure
JP2019501867A5 (enExample)
RU2016110153A (ru) Новые пептиды и их аналоги для применения при лечении мукозита полости рта
JP2012516693A5 (enExample)
RU2018140501A (ru) Пэгилированные биологически активные пептиды и их применение
JP2018511326A5 (enExample)
JP2020515283A5 (enExample)